Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • 2025
  • Page 117
ash:-anito-cel-strengthens-best-in-class-potential-as-gilead’s-kite-preps-for-launch
Posted inBiotechnology

ASH: Anito-cel strengthens best-in-class potential as Gilead’s Kite preps for launch

December 7, 2025
ORLANDO, Fla. —The leader of Gilead’s Kite Pharma is sure that anito-cel, the biotech’s next-generation multiple myeloma CAR-T challenger to…
Read More
ash:-star-antibody-sparkles-in-preview-of-potential-phase-3-bleeding-disease-success
Posted inBiotechnology

ASH: Star antibody sparkles in preview of potential phase 3 bleeding disease success

December 6, 2025
ORLANDO, Fla. — With dosing underway in a pivotal phase 3 trial, Star Therapeutics is illuminating the clinical potential of…
Read More
antibody-blocks-triple-negative-breast-cancer-growth-and-metastasis-in-mice
Posted inGenetics

Antibody Blocks Triple-Negative Breast Cancer Growth and Metastasis in Mice

December 5, 2025
Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant forms of breast cancer. It grows quickly, spreads…
Read More
fda-panel-votes-against-j&j’s-novel-shunt-implant-for-heart-failure
Posted inMedical Technology

FDA panel votes against J&J’s novel shunt implant for heart failure

December 5, 2025
Johnson & Johnson’s billion-dollar bet on a novel implant for heart failure hit a roadblock this week, with an FDA…
Read More
lung-organoids,-autism-and-sarcopenia-insights-in-mice,-and-a-bidding-war-ends
Posted inGenetics

Lung Organoids, Autism and Sarcopenia Insights in Mice, and a Bidding War Ends

December 5, 2025
Stories on lung organoids and autism were some of the most read this week. We kicked things off by digging…
Read More
ash:-novartis-details-ianalumab’s-phase-3-win-in-rare-blood-disease
Posted inBiotechnology

ASH: Novartis details ianalumab’s phase 3 win in rare blood disease

December 5, 2025
ORLANDO, Fla.—Novartis is divulging details from ianalumab’s summertime phase 3 win in a rare autoimmune blood disorder, and the data…
Read More
‘unprecedented-turmoil’-engulfing-fda-threatens-public-health:-mrna-coalition-speaks-out
Posted inBiotechnology

‘Unprecedented turmoil’ engulfing FDA threatens public health: mRNA coalition speaks out

December 5, 2025
The industry’s mRNA alliance is demanding steady FDA leadership, warning that the current “unprecedented turmoil” at the agency is eroding…
Read More
natera-buys-foresight-diagnostics-in-cancer-testing-deal-worth-up-to-$450m
Posted inMedical Technology

Natera buys Foresight Diagnostics in cancer testing deal worth up to $450M

December 5, 2025
Natera is looking to grow its portfolio of tools to detect the recurrence of cancer with a deal to acquire…
Read More
‘market’s-thinking-is-backwards’:-fda’s-1-trial-approval-plan-would-boost-r&d-spend,-jefferies-says
Posted inBiotechnology

‘Market’s thinking is backwards’: FDA’s 1-trial approval plan would boost R&D spend, Jefferies says

December 5, 2025
The FDA’s reported plan to move toward single-trial approvals has stirred industry concern, but one group of analysts views the…
Read More
encoded-deciphers-path-to-pivotal-trial-with-phase-1/2-dravet-gene-therapy-data
Posted inBiotechnology

Encoded deciphers path to pivotal trial with phase 1/2 Dravet gene therapy data

December 5, 2025
Encoded Therapeutics has linked its Dravet syndrome gene therapy ETX101 to a 78% reduction in seizures, keeping the biotech on…
Read More

Posts pagination

Previous page 1 … 115 116 117 118 119 … 1,169 Next page

Privacy Policy    Terms

Scroll to Top